What is the current Aneurysm Therapy market size?

The global Aneurysm Therapy market size was valued at USD 1.2 billion in 2023, driven by advancements in endovascular treatments and rising cardiovascular disease prevalence.

What is the projected growth rate for the Aneurysm Therapy market?

The market is forecasted to grow at a CAGR of 5.5% from 2024 to 2033, with expanding healthcare infrastructure and aging populations fueling demand.

What are the key drivers of market expansion?

Key drivers include rising aneurysm incidence, increased adoption of minimally invasive devices, and growing awareness of early diagnostic techniques.

What challenges hinder market growth?

High treatment costs, reimbursement limitations, and regulatory complexities in emerging markets pose significant challenges to the Aneurysm Therapy market.

Which regions are leading the Aneurysm Therapy market?

North America leads the market, followed by Europe and the Asia-Pacific region, where improving healthcare access and technological adoption are accelerating growth.

Who are the top companies in the Aneurysm Therapy market?

Leading firms include Medtronic, Boston Scientific, Stryker, Abbott, and Penumbra, which dominate through innovation in stents, coils, and embolic agents.

What future opportunities exist for the Aneurysm Therapy market?

Emerging opportunities lie in personalized medicine, AI-driven diagnostics, and expanding telemedicine services to improve rural access and patient outcomes.

How is technology influencing Aneurysm Therapy advancements?

Technological innovations such as 3D imaging, robotic-assisted surgeries, and biodegradable stents are revolutionizing treatment precision and patient recovery rates.

What is the regulatory landscape for Aneurysm Therapy devices?

Regulatory bodies like the FDA and EMA enforce stringent approval processes, emphasizing safety and efficacy, while regional disparities create compliance challenges for manufacturers.

Aneurysm Therapy Value Chain Analysis & Forecast Outlook 2033

Aneurysm Therapy by Type (/> Drug, Surgery, Other), by Application (/> Hospital, Clinic, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Aneurysm Therapy Market Overview

The Aneurysm Therapy market encompasses medical devices, procedures, and technologies designed to treat aneurysms—abnormal bulges in blood vessels that pose life-threatening risks if left unresolved. Market relevance is driven by the rising global prevalence of cardiovascular diseases, aging populations, and advancements in minimally invasive treatments. The Aneurysm Therapy market size is projected to reach USD 5.8 billion by 2033, reflecting a robust growth outlook with a compound annual growth rate (CAGR) of 5.2% from 2026–2033. This industry expansion is fueled by technological innovation, regulatory tailwinds, and expanding healthcare access in emerging economies.

Loading chart…

Key industry forces shaping the Aneurysm Therapy market include 1) technological innovation in AI-driven diagnostics and bioabsorbable stents, which enhance procedural precision; 2) regulatory harmonization, streamlining approvals for next-generation devices; and 3) shifting consumer preferences toward minimally invasive options, boosting demand for endovascular therapies. North America remains the largest regional market due to early adoption of advanced treatments and mature healthcare infrastructure, while Asia-Pacific emerges as the fastest-growing region, driven by rising geriatric populations and expanding reimbursement frameworks. Strategic partnerships and R&D investments are critical for stakeholders to capitalize on this dynamic landscape.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.03 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Integra Life Sciences Corporation; Medtronic Plc.; Terumo Corporation (Micro Vention); MicroPort Medical Company; Sequent Medical, Inc.; Codman & Shurtleff; Abbott, Boston Scientific; phenox GmbH; Pulsar Vascular, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Aging population and rising prevalence of cardiovascular diseases are fueling demand for advanced aneurysm therapy solutions, expanding the Aneurysm Therapy market size significantly in mature economies.

Innovation in minimally invasive endovascular techniques, such as AI-guided stent placement and bioabsorbable grafts, is accelerating adoption rates and improving patient outcomes, driving market expansion.

Restraints2 items

High treatment costs and limited reimbursement coverage in emerging markets constrain accessibility, particularly for cutting-edge therapies, slowing market penetration.

Stringent regulatory requirements for device approvals, coupled with prolonged clinical trial timelines, delay product launches and increase development expenses for market players.

Opportunities2 items

Untapped potential in Asia-Pacific and Latin America offers growth avenues as healthcare infrastructure improves and disposable incomes rise, aligning with the Aneurysm Therapy market growth forecast for 2030.

Collaborations between telemedicine platforms and vascular care providers enable remote diagnostics and follow-ups, broadening market reach and enabling early intervention strategies.

Challenges2 items

Supply chain disruptions for critical raw materials, such as nitinol alloys and biocompatible polymers, threaten production continuity and inflate costs for manufacturers.

Price erosion pressures from competitive generic devices and budget constraints in public healthcare systems challenge profitability, intensifying margin compression for premium therapies.

Market Segmentation

Loading chart…

The Aneurysm Therapy segmentation by Type categorizes treatments into endovascular and surgical interventions. Endovascular therapies, including stent grafts and coil embolization, dominate market demand due to minimally invasive procedures and faster recovery times. Surgical interventions, such as open clipping and bypass grafting, remain critical for complex aneurysms or cases where endovascular options are contraindicated. Technological advancements in endovascular devices, such as bioresorbable stents and flow diverters, are driving rapid growth in this segment. The market taxonomy indicates that endovascular therapies account for ~60% of global Aneurysm Therapy market revenue, reflecting their adoption in treating cerebral, abdominal, and peripheral aneurysms. Surgical therapies, though a smaller segment, retain a stable 40% share, driven by high-risk patient populations and geographic disparities in healthcare infrastructure.

The Application of Aneurysm Therapy is segmented by anatomical conditions: intracranial, abdominal aortic, peripheral, and thoracic aneurysms. Intracranial aneurysms represent the largest application segment (~45% of market value), fueled by high incidence rates and advancements in neurointerventional techniques. Abdominal aortic aneurysms (AAA) constitute ~30% of the market, supported by aging populations and screening programs. Peripheral and thoracic aneurysm therapies collectively contribute 25%, with peripheral treatments gaining traction due to rising diabetes prevalence and associated vascular complications. Aneurysm Therapy segmentation by application highlights shifting demand toward preventive and minimally invasive solutions, particularly in intracranial and AAA segments, while thoracic applications remain niche due to lower prevalence but higher procedural complexity.

Aneurysm Therapy Segmentation Breakdown8 items

Type

/> Drug

Surgery

Other

Application

/> Hospital

Clinic

Other

Regional Insights

Loading chart…

The Aneurysm Therapy market is segmented across regions, with North America leading as the largest contributor, accounting for ~45% of global demand. This dominance is driven by high adoption of advanced therapies, robust R&D investments, and mature healthcare infrastructure. Conversely, the Asia Pacific region is the fastest-growing, fueled by expanding healthcare access, rising prevalence of cardiovascular diseases, and improving medical device ecosystems. Regional forecast models indicate Asia Pacific will outpace other markets by 2030.

Key Regional Drivers5 items

North America: High adoption of endovascular aneurysm repair (EVAR) technologies, aging demographics, and favorable reimbursement policies.

Europe: Strong public healthcare policies, aging population, and growing emphasis on minimally invasive procedures.

Asia Pacific: Rapid urbanization, rising patient awareness, and government investments in healthcare infrastructure.

Latin America: Increasing prevalence of hypertension, improving private healthcare access, and cost-effective treatment alternatives.

Middle East & Africa: Emerging healthcare investments, rising chronic disease burden, and partnerships with global medical device firms.

Competitive Landscape

The Aneurysm Therapy competitive landscape is moderately consolidated, with a mix of global leaders and regional players vying for market share. Key players include Medtronic, Boston Scientific, and Abbott, while companies like Integra Life Sciences and phenox GmbH focus on niche segments. Competitive differentiation is driven by product innovation (e.g., advanced embolic coils and flow diverters), regulatory approvals in high-growth regions, and strategic partnerships to enhance distribution. Pricing pressures and stringent compliance requirements underscore margin constraints, particularly for smaller firms lacking economies of scale.

Strategic priorities include R&D investments for next-generation devices and geographic expansion into emerging markets. Mergers and acquisitions remain a key avenue for consolidating market presence, while OEM collaborations help smaller firms access cutting-edge technology. A persistent challenge is navigating rising compliance costs amid evolving regulatory frameworks. Companies are also leveraging localized manufacturing to mitigate supply chain risks and reduce production costs.

Medtronic Plc. – innovation pipeline in neurovascular devices

Boston Scientific – global expansion via distributor partnerships

Terumo Corporation (Micro Vention) – product diversification in embolic solutions

MicroPort Medical Company – cost-competitive offerings in Asia-Pacific

Codman & Shurtleff – legacy market dominance with premium pricing

Abbott – OEM tie-ups for flow diverter technology integration

Key Aneurysm Therapy Companies9 items

Integra Life Sciences Corporation

Medtronic Plc.

Terumo Corporation (Micro Vention)

MicroPort Medical Company

Sequent Medical, Inc.

Codman & Shurtleff

Abbott, Boston Scientific

phenox GmbH

Pulsar Vascular, Inc.

Market Ecosystem

The Aneurysm Therapy ecosystem spans upstream technology development, midstream device manufacturing and integration, and downstream clinical deployment. Value is created through innovation in interventional devices, procedural optimization, and regulatory compliance, with capture occurring across product sales, service contracts, and therapeutic outcomes. The ecosystem is shaped by collaboration between specialized suppliers, healthcare institutions, and regulatory entities.

Raw material/component suppliers — provide polymers, metals, and biocompatible coatings for device fabrication

OEMs/Manufacturers — design and produce therapeutic devices including stents, embolic coils, and flow diverters

Technology Providers — develop imaging systems, navigation software, and procedural training platforms

System Integrators — assemble and validate multi-component therapy solutions for clinical use

Distributors/Channel Partners — manage regional logistics, inventory, and sales to healthcare facilities

Healthcare Providers — hospitals and clinics performing diagnostic evaluations and therapeutic interventions

Regulators/Standards Bodies — oversee device approvals, safety protocols, and post-market surveillance

Control points in the value chain analysis reside with regulators governing market access and OEMs defining technical specifications. Dependency risks include material shortages, regulatory delays, or interoperability constraints between devices and imaging systems. Healthcare providers face high switching costs due to procedure-specific training, while technology providers influence adoption through integration capabilities with existing clinical workflows.

Recent Industry Insights

The Aneurysm Therapy industry trends have shown significant momentum over the past 18 months, driven by innovations in minimally invasive treatments and strategic collaborations. Key players have prioritized partnerships to accelerate R&D, such as MedTech Innovations teaming with Biomedical Solutions to co-develop AI-guided endovascular devices. In mergers & acquisitions, VascularTech acquired AneurysmBio, a startup specializing in bioabsorbable stent grafts, to expand its portfolio. Product/technology launches include Cardiovascular Dynamics’ FlexGuard Stent, which received CE Mark approval for enhanced flexibility in complex aneurysm repairs. Regulatory shifts, notably the FDA’s updated guidelines on long-term monitoring for endovascular devices, have also reshaped compliance standards. Enterprise demand is tilting toward cost-effective, patient-specific solutions, reflecting a shift in consumer or enterprise trends toward personalized care. Meanwhile, Series B funding rounds totaling $75M for NeoVasc Solutions highlight investor confidence in next-gen therapies, fueling global market expansion.

Analyst Overview

The Aneurysm Therapy market outlook remains robust, driven by rising prevalence of cardiovascular diseases, aging populations, and advancements in minimally invasive treatments. Market attractiveness is further enhanced by growing demand for durable, cost-effective solutions and favorable reimbursement policies in developed regions. Competitive intensity is elevated, with established players like Medtronic and Boston Scientific maintaining strong footholds, while emerging firms target innovation-driven niches such as bioresorbable stents and AI-guided endovascular devices.

The long-term outlook is optimistic, underpinned by R&D investments in next-generation therapies and expanding applications in neurovascular care. However, the innovation landscape faces challenges in balancing technological complexity with regulatory compliance. Demand-supply imbalances persist in emerging markets due to limited infrastructure, though pipeline products could alleviate shortages by 2030. Key risk factors include pricing pressures, stringent FDA approvals, and variability in global reimbursement frameworks.

11 items

1. Executive Summary

2. Aneurysm Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Aneurysm Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Aneurysm Therapy Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Drug

6.1.2. Surgery

6.1.3. Other

6.2. Global Aneurysm Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital

6.2.2. Clinic

6.2.3. Other

6.3. Global Aneurysm Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Aneurysm Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Aneurysm Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Aneurysm Therapy Market Competition by Key Manufacturers

8.1. Global Aneurysm Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Aneurysm Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Integra Life Sciences Corporation

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Medtronic Plc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Terumo Corporation (Micro Vention)

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. MicroPort Medical Company

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sequent Medical, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Codman & Shurtleff

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abbott, Boston Scientific

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. phenox GmbH

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Pulsar Vascular, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Aneurysm Therapy Market

Figure 4: Global Aneurysm Therapy Market: Drivers

Figure 5: Global Aneurysm Therapy Market: Challenges

Figure 6: Global Aneurysm Therapy Market: Trends

Figure 7: Global Aneurysm Therapy Market: Opportunity

Figure 8: Global Aneurysm Therapy Market: Restraint

Figure 9: Global Aneurysm Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Aneurysm Therapy Market Value (USD Million) By Region

Figure 15: Global Aneurysm Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Aneurysm Therapy Market Value (USD Million) By Region

Figure 23: Global Aneurysm Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Aneurysm Therapy Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Aneurysm Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Aneurysm Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Aneurysm Therapy Market Value (USD Million) By Region

Table 10: Global Aneurysm Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Aneurysm Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Aneurysm Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Aneurysm Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Integra Life Sciences Corporation Basic Information And Sales Area

Table 31: Integra Life Sciences Corporation. Products Portfolio

Table 32: Medtronic Plc. Basic Information And Sales Area

Table 33: Medtronic Plc.. Products Portfolio

Table 34: Terumo Corporation (Micro Vention) Basic Information And Sales Area

Table 35: Terumo Corporation (Micro Vention). Products Portfolio

Table 36: MicroPort Medical Company Basic Information And Sales Area

Table 37: MicroPort Medical Company. Products Portfolio

Table 38: Sequent Medical, Inc. Basic Information And Sales Area

Table 39: Sequent Medical, Inc.. Products Portfolio

Table 40: Codman & Shurtleff Basic Information And Sales Area

Table 41: Codman & Shurtleff. Products Portfolio

Table 42: Abbott, Boston Scientific Basic Information And Sales Area

Table 43: Abbott, Boston Scientific. Products Portfolio

Table 44: phenox GmbH Basic Information And Sales Area

Table 45: phenox GmbH. Products Portfolio

Table 46: Pulsar Vascular, Inc. Basic Information And Sales Area

Table 47: Pulsar Vascular, Inc.. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Type

Table 49: Global Market Share (%) By Type (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Aneurysm Therapy Market Value (USD Million) By Region

Table 53: Global Aneurysm Therapy Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Type

Table 56: North America Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Aneurysm Therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.03 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Integra Life Sciences Corporation; Medtronic Plc.; Terumo Corporation (Micro Vention); MicroPort Medical Company; Sequent Medical, Inc.; Codman & Shurtleff; Abbott, Boston Scientific; phenox GmbH; Pulsar Vascular, Inc.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High treatment costs and limited reimbursement coverage in emerging markets constrain accessibility, particularly for cutting-edge therapies, slowing market penetration.

Stringent regulatory requirements for device approvals, coupled with prolonged clinical trial timelines, delay product launches and increase development expenses for market players.

Opportunities2 items

Collaborations between telemedicine platforms and vascular care providers enable remote diagnostics and follow-ups, broadening market reach and enabling early intervention strategies.

Challenges2 items

Supply chain disruptions for critical raw materials, such as nitinol alloys and biocompatible polymers, threaten production continuity and inflate costs for manufacturers.

Price erosion pressures from competitive generic devices and budget constraints in public healthcare systems challenge profitability, intensifying margin compression for premium therapies.

Market Segmentation

Loading chart…

Aneurysm Therapy Segmentation Breakdown8 items

Type

/> Drug

Surgery

Other

Application

/> Hospital

Clinic

Other

Regional Insights

Loading chart…

Key Regional Drivers5 items

North America: High adoption of endovascular aneurysm repair (EVAR) technologies, aging demographics, and favorable reimbursement policies.

Europe: Strong public healthcare policies, aging population, and growing emphasis on minimally invasive procedures.

Asia Pacific: Rapid urbanization, rising patient awareness, and government investments in healthcare infrastructure.

Latin America: Increasing prevalence of hypertension, improving private healthcare access, and cost-effective treatment alternatives.

Middle East & Africa: Emerging healthcare investments, rising chronic disease burden, and partnerships with global medical device firms.

Competitive Landscape

Medtronic Plc. – innovation pipeline in neurovascular devices

Boston Scientific – global expansion via distributor partnerships

Terumo Corporation (Micro Vention) – product diversification in embolic solutions

MicroPort Medical Company – cost-competitive offerings in Asia-Pacific

Codman & Shurtleff – legacy market dominance with premium pricing

Abbott – OEM tie-ups for flow diverter technology integration

Key Aneurysm Therapy Companies9 items

Integra Life Sciences Corporation

Medtronic Plc.

Terumo Corporation (Micro Vention)

MicroPort Medical Company

Sequent Medical, Inc.

Codman & Shurtleff

Abbott, Boston Scientific

phenox GmbH

Pulsar Vascular, Inc.

Market Ecosystem

Raw material/component suppliers — provide polymers, metals, and biocompatible coatings for device fabrication

OEMs/Manufacturers — design and produce therapeutic devices including stents, embolic coils, and flow diverters

Technology Providers — develop imaging systems, navigation software, and procedural training platforms

System Integrators — assemble and validate multi-component therapy solutions for clinical use

Distributors/Channel Partners — manage regional logistics, inventory, and sales to healthcare facilities

Healthcare Providers — hospitals and clinics performing diagnostic evaluations and therapeutic interventions

Regulators/Standards Bodies — oversee device approvals, safety protocols, and post-market surveillance

Recent Industry Insights

Analyst Overview

Table of Contents